SCHEMBL5284040

SCHEMBL5284040

O=S(=O)(Nc1ccc(F)cc1)c1ccc(N2CCOCC2)c2nonc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.59
MAPT P10636 6/20 0.59
MEN1 O00255 5/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
GAA P10253 2/20 0.59
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
ALDH1A1 P00352 3/20 0.55
NLRP3 Q96P20 1/20 0.51
THRB P10828 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
POLB P06746 1/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48
LMNA P02545 2/20 0.44
KDM4E B2RXH2 1/20 0.43
MAPK1 P28482 1/20 0.43
MCL1 Q07820 1/20 0.43
TP53 P04637 1/20 0.43
RORA P35398 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5291658 0.82 NLRP3 (0.49) KMT2AMAPTMEN1SMN1; SMN2GAA
SCHEMBL8268839 0.80 MAPT (0.62) KMT2AMAPTMEN1SMN1; SMN2GAA
SCHEMBL5246860 0.77 MAPT (0.51) KMT2AMAPTMEN1SMN1; SMN2GAA
SCHEMBL6389762 0.74 GAA (0.45) KMT2AMAPTMEN1SMN1; SMN2GAA
SCHEMBL5289074 0.73 KMT2A (0.55) KMT2AMAPTMEN1SMN1; SMN2ALDH1A1
SCHEMBL5286591 0.73 MAPT (0.55) KMT2AMAPTMEN1SMN1; SMN2ALDH1A1
SCHEMBL6392954 0.73 MAPT (0.59) KMT2AMAPTMEN1SMN1; SMN2GAA
SCHEMBL5287661 0.72 SLC40A1 (0.46) KMT2AMAPTMEN1SMN1; SMN2GAA
SCHEMBL5243508 0.72 NLRP3 (0.50) KMT2AMAPTMEN1SMN1; SMN2GAA
SCHEMBL5245942 0.72 ALDH1A1 (0.46) KMT2AMAPTMEN1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP KMT2A 1303/4885MAPT 1681/4885MEN1 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.